Evidence map›Paper›PMID 32709234›Full record

ArticleBMC health services research2020

Development and evaluation of a bladder Cancer specific survivorship care plan by patients and clinical care providers: a multi-methods approach.

Cheryl T Lee, Nihal E Mohamed, Sailaja Pisipati, Qainat N Shah, Piyush K Agarwal, Tracy M Downs, Michael Droller, Scott M Gilbert, Heather H Goltz, Simon J Hall and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC health services research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Cheryl T LeeDepartment of Urology, The Ohio State University, Columbus, OH, USA.
Nihal E MohamedDepartment of Urology and Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Place, New York, NY, 10029, USA. nihal.mohamed@mountsinai.org.
Sailaja PisipatiUniversity of Nevada Reno School of Medicine, Reno, NV, USA.
Qainat N ShahDepartment of Urology and Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Place, New York, NY, 10029, USA.
Piyush K AgarwalNational Cancer Institute, Bethesda, MD, USA.
Tracy M DownsUniversity of Wisconsin, Madison, WI, USA.
Michael DrollerDepartment of Urology and Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Place, New York, NY, 10029, USA.
Scott M GilbertMoffitt Cancer Center, Tampa, FL, USA.
Heather H GoltzSocial Work Program, University of Houston-Downtown, Houston, TX, USA.
Simon J HallSmith Institute for Urology, Hofstra School of Medicine/Northwell Health System, Lake Success, NY, USA.
Mohamed HendawiDepartment of Urology, The Ohio State University, Columbus, OH, USA.
Jean Hoffman-CensitsSidney Kimmel Cancer Center at John Hopkins, Baltimore, MD, USA.
Michael O'DonnellUniversity of Iowa, Iowa City, IA, USA.
Matthew KaagPenn State Health, Hershey, PA, USA.
Lawrence I KarshThe Urology Center of Colorado, Denver, CO, USA.
Wassim KassoufMcGill University Health Center, Montreal, Canada.
Diane Z QualeBladder Cancer Advocacy Network, Bethesda, MD, USA.
Arthur SagalowskyUniversity of Texas, Southwestern, Dallas, TX, USA.
Gary D SteinbergNYU Langone Health, New York, NY, USA.
David M LatiniBaylor College of Medicine, Houston, TX, USA.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
Bladder Cancer Advocacy Network Small grant of $50000 without number dates Sept 2010 - June 2014NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

BACKGROUND, CONTEXT AND PURPOSE: In spite of the mixed evidence for their impact, survivorship Care Plans (SCPs) are recommended to enhance quality of care for cancer survivors. Data on the feasibility of SCPs in bladder cancer (BC) is sparse. Using a mixed-methods approach, this study describes the iterative development, acceptability and feasibility of BC specific SCP (BC-SCP) in clinical settings.

methodsIn Phase I, we developed the BC-SCP. In Phase II, we conducted four focus groups with 19 patients and 15 providers to examine its acceptability and usability challenges. Data analyses using the Atlas.ti program, informed refinement of the BC-SCP. In Phase III, we conducted feasibility testing of the refined BC-SCP with 18 providers from 12 health-centers. An encounter survey was completed after each assessment to examine the feasibility of the BC-SCP. Chi-square and Fisher Exact tests were used for comparative analyses.

resultsDuring phase I, we observed high patient and provider acceptability of the BC-SCP and substantial engagement in improving its content, design, and structure. In Phase II, providers completed 59 BC-SCPs. Mean time for BC-SCP completion was 12.3 min. Providers reported that BC-SCP content was clear, did not hamper clinic flow and was readily completed with easy-to-access information. Comparative analyses to examine differences in SCP completion time by patient clinico-demographic characteristics and provider type revealed no significant differences.

conclusionsOur BC-SCP has clinical relevance, and can be used in an active practice setting. However, considerable progress will be necessary to achieve implementation of and sharing the BC-SCP with patients and care providers, particularly within the electronic medical record. In summary, BC-SCPs are essential to improve the follow up care of BC survivors. Clinical resources are required to ensure appropriate implementation of BC-SCPs.

trial registrationStudy HUM00056082.

Indexed as

SurvivorshipAgedCancer SurvivorsFeasibility StudiesFemaleFocus GroupsHealth Care SurveysHealth PersonnelHumansMaleMiddle AgedPatient Acceptance of Health CarePatient Care PlanningQualitative ResearchUrinary Bladder NeoplasmsBladder Cancer specific survivorship care planCare providersFocus groupsMuscle invasive bladder CancerNon-muscle invasive bladder CancerSurvivorship care plan

Identifiers

PMID32709234
PMCPMC7379822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.